+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 99Years
All Genders
ID07392658

Phase II Study of Amivantamab With Single-Agent Chemotherapy for Adults with Metastatic Non-Small Cell Lung Cancer Having EGFR exon20 Insertion Mutations and Unfit for Platinum Chemotherapy

Led by Fondazione Ricerca Traslazionale · Updated on 2026-02-06

33

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of amivantamab combined with single-agent chemotherapy in patients with metastatic non-small cell lung cancer NSCLC who have EGFR exon20 insertion mutations and are unable to receive platinum-based chemotherapy. This phase II multicenter study focuses on determining response rates, progression-free survival, and overall survival in this specific patient group. Participants will receive subcutaneous amivantamab at an initial dose of 1600 mg or 2240 mg for those weighing 80 kg or more on the first day of treatment cycle 1, followed by 2400 mg or 3360 mg for those 80 kg or more on days 8 and 15 of cycle 1. Starting from cycle 2 day 1, amivantamab is administered every three weeks alongside a single chemotherapy drug, either pemetrexed or gemcitabine, selected by the investigator. Treatment continues until disease progression, unacceptable side effects, or patient choice to stop. Throughout the study, disease status will be assessed every eight weeks using imaging criteria RECIST version 1.1, and side effects will be monitored according to standard toxicity guidelines NCI CTCAE version 5.0. The main outcome measure is the objective response rate assessed through the duration of the study, approximately one year. Participants will be closely observed for treatment effects and safety during their involvement in the trial, which is expected to last until disease progression or other discontinuation reasons.

CONDITIONS

Brief Title

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

Research Team

F

Federico Cappuzzo

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here